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In spite ofnumerous studies, epidemiology
has failed to provide unequivocal evidence
of an association between 60-Hz magnetic
fields (MF) and cancer (1-3). Partly in
response to this continuing ambiguity, lab-
oratory experiments were begun at Health
Canada in 1989 to assess the effect of MF
on tumorigenesis in mice. At that time,
there were indications that MF alone could
not directly initiate cancer (4,5). Accord-
ingly, an experiment was designed to test
the effect ofMF on tumor promotion using
the well-known SENCAR mouse two-stage
(initiation/promotion) skin tumor model
(6,7). In this previously published prelimi-
nary experiment (7), the dorsal skin ofmice
was exposed to a single dose of 7,12-
dimethylbenz[a]anthracene (DMBA) and
then mice were randomly distributed to two
treatment groups. One group received sham
exposures and the other received MF expo-
sures (2 mT, 60-Hz); both groups received
topical applications ofphorbol 12-myristate
13-acetate (PMA) at a dose rate of 1
pg/week (7). The proportion of mice with
one or more tumors (tumor incidence) in
this preliminary experiment was well above
80% halfway through the promotion period
and exceeded 90% at the end of20 weeks.
The experimental design, as previously dis-
cussed (7), considered tumor incidence the
most important measure of a putative
tumor co-promoter, while tumor multiplic-
ity (the average number of tumors per
mouse) and tumor yield (the distribution of
the total number of tumors in the two
groups) were considered secondary.
Therefore, to detect an increase in tumor
incidence that could be reasonably attrib-
uted to MF, the proportion ofmice devel-
oping tumors in the sham group had to be
kept well below 0.80 (e.g., at 0.2-0.3). To
attain this low tumor incidence over three
independently replicated experiments, the
dose rate of PMA was reduced to 0.3
jig/week after appropriate preliminary trials
[described by Stuchly et al. (8)]. Results
have been published for the preliminary
experiment (7), which used a saturating
dose rate ofPMA (1 pg/week), and for the
first of three replicate experiments involv-
ing PMA at a dose rate of0.3 pg/week (8).
The data discussed here were derived only
from the three replicate experiments all
using the same reduced dose rate ofPMA.
Materials and Methods
Experimental design and statistical analy-
sis. Three measures were used to assess the
ability of MF to act as a co-promoter: the
proportion of mice that developed one or
more tumors (tumor incidence), the distri-
bution of tumor counts between groups
(tumor yield), and the number of tumors
per mouse (tumor multiplicity). Tumor
incidence could be kept relatively low, in
the area of 0.2-0.3, by reducing the dose
rate of PMA from 1 to 0.3 pg/week (8).
To consider MF as a tumor co-promoter
under these experimental conditions, the
tumor incidence in the sham- and MF-
exposed groups had to differ by no less
than a factor of2. For a group of48 mice
(with no allowance for possible mouse-to-
mouse variability), the probability of
rejecting the null hypothesis, if true, was
set at 5% (a = 0.05). This would allow the
alternative hypothesis to be accepted 80%
of the time when the groups differed by a
factor of 2 (i.e., ,B = 0.20). Differences in
tumor incidence between the two groups in
the three experiments were tested using
either Fisher's exact method for a 2 x 2
table or Zelen's method for the analysis of
several 2 x 2 tables (9). The number of
tumors per mouse did not follow a Poisson
distribution, and specialized methods were
required to take into account the observed
variation (10).
Exposure chambers. The construction
and characteristics of the exposure cham-
bers have been described in detail elsewhere
(6). Briefly, the MF in the exposure volume
was generated by a double set of square
coils, each consisting offour windings on a
wooden frame. This configuration was used
to minimize stray MF outside the exposure
system and to provide a uniform field with-
in the volume occupied by 16 mouse cages.
The coils were water cooled and consisted
of plastic-insulated copper tubing. Current
to the coils was provided by a transformer
(Hammond model EP4EA120/240-12/24-
1500 VA; Hammond Manufacturing,
Guelph, Ontario) connected to a standard
110 V, 15 AAC outlet. The MF had a
mean flux density of 2 mT that varied < ±
10% within the volume occupied by the
cages. The electric field was minimized by
shielding the windings with thin copper
tape. The current in the coils, the magnetic
flux density in the exposure chambers, and
the light level and temperature in the expo-
sure room were recorded every 20 min by
an on-site computer and routinely moni-
tored off-site by a system that had been
developed jointly with Ottawa Instrumen-
tation Inc., Ottawa, Ontario. The exposure
cages were made from acrylic (0.1 m x 0.25
m x 0.18 m) and contained a series of 7-
mm diameter holes to facilitate air flow to
the mice.
Chemicals and the treatment ofmice.
DMBA was obtained from Aldrich
Chemical Company (St. Louis, MO) at a
purity of >98%, and PMA from L.C.
Laboratories, (Woburn, MA). DMBA was
dissolved in acetone, protected from light,
used within 2 hr ofpreparation, and applied
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to the dorsal skin of mice under subdued
light. PMA was prepared as a 1 mg/ml
stock solution in acetone, stored at -300C,
and diluted with acetone immediately
before use. SENCAR mice were acquired
from Harlan Sprague-Dawley (Indianapolis,
IN) at 5 weeks ofage and allowed to accli-
matize at 3 mice/cage. Tumorigenesis was
initiated on the shaved backs ofmice by the
topical application of 10 nmol DMBA at
the estimated start ofthe third resting phase
ofthe hair cycle (7). Five days after DMBA
treatment, mice with visible signs of hair
regrowth were eliminated from the study;
the rest were randomly distributed into two
groups of48 mice each. Mice were assigned
to specific home and exposure cages and
identified within cages byear punch.
One week following initiation, both
groups were treated with PMA for 23 weeks
at a dose rate of 0.3 pg/week (8). During
this period oftumor promotion, one group
ofmice was exposed to a 2 mT, 60-Hz MF
for 6 hr/day, 5 days/week, and the other
group was exposed to sham conditions. All
mice were exposed during the light cycle
from 8:00 A.M. to 2:00 P.M. (dark cycle,
6:00 P.M.-6:00 A.M.). The exposure dura-
tion and the magnetic flux density were
selected to simulate intense occupational
exposures. In scaling from man to mouse,
the maximum current loop radius was
assumed to be proportional to the cube root
of the body weight. Under this condition,
the scaling factor was estimated at 12-14 for
an average 70 kg man and for the range of
body weights for mice of25-40 g. Thus, 2
mT for mice corresponds to approximately
0.15 mT for adult human males, which rep-
resents an intense occupational exposure.
Mice had free access to Purina rodent chow
(PMI Feeds, Richmond, IN) and water in
their home cages and only to food in the
exposure cages. Theywere housed according
to Canadian standards (11). In the first (d)
and third replicate experiments, PMA was
applied at mid-week, 1 hr into the light
phase and 0.5-1 hrbefore the start ofMF or
sham exposures. In the second experiment,
PMAwas applied at mid-week 1 hr after the
cessation of the MF and sham treatments
(i.e., between 2:00 and 3:00 P.M.). Dorsal
hair was removed from each mouse with
electric clippers 1 day before PMA applica-
tion. Tumor counts were recorded every
week and body weights every second week.
To be considered part of the data set, a
tumor had to attain a diameter of >1 mm
and remain at the original site for 3 consecu-
tive weeks. The location, size, and morphol-
ogy of all tumors were recorded weekly for
each mouse by a computer-based imaging/
archiving system, which was developed in
collaboration with Ottawa Instrumentation.
Results
The results for tumor incidence, multiplicity,
and yield at week 23 are shown in Table 1.
Ofthe 284 mice that survived 23 weeks, 62
(21.8%) responded to tumor promotion,
with 34 tumor-bearing mice in the sham and
28 in the group exposed to MF. There were
146 tumors in the 141 mice exposed to MF
and 184 tumors in the 143 mice exposed to
sham conditions. From pooled data to week
23, the tumor incidence was 23.8% for
sham-exposed mice and 19.8% for those
exposed to MF (Table 1). The mean number
of tumors in mice with one or more tumors
was 5.2 for those exposed to MF and 5.4 for
sham. A test for heterogeneity ofthe differ-
ences in incidences between MF and sham
groups across the three experiments yielded p
= 0.07. While not significant, this value was
sufficiently close to the traditional p<0.05
level to rule out further statistical tests on
pooled data.
When individual experiments are consid-
ered at week 23, the differences in tumor
incidences (Table 1) between the MF and
sham groups were not statistically significant
for the first andsecondexperiments (p = 0.34
and p = 1.0, respectively). However, for the
last experiment, the tumor incidence was
significantly higher for mice exposed under
sham conditions (p = 0.04). The distribu-
tion of tumor counts (tumor yield) among
sham and MF-exposed mice ofeach experi-
ment at week 23 is shown in Table 1. The
variation in the counts was greater than
that expected for a Poisson distribution. As
a result, the differences in tumor yield
between the MF and sham groups were
tested using statistical methods that
allowed for this additional variation (10).
By these methods, the significance ofthese
differences were 0.15, 0.26, and 0.01 for
the first, second, and third experiments,
respectively. Again, the lowest significance
was associated with the third experiment in
which the tumor yield in the sham group
exceeded that in the mice exposed to MF.
Discussion
In a previous experiment (7), an MF alone
was unable to promote the growth of skin
tumors on DMBA-initiated SENCAR mice
or to enhance the action of high doses of
the tumor promoter PMA (7,12). The data
compiled from the three replicate experi-
ments are further evidence in support ofthe
contention that MF is not a skin tumor co-
promoter under these experimental condi-
tions. For the experimental design to detect
a moderate effect of MF on tumor inci-
dence, the proportion ofmice with tumors
in the three replicate shams had to be kept
low, preferably in the range of0.2-0.3, and
relatively stable from experiment to experi-
ment. The large variation in tumor counts
that existed between the three sham groups
and the need to keep tumor incidences low
in the shams combined to severely limit the
ability ofthe experimental design to detect
small differences between the sham and MF
exposed groups.
The lack ofany significant difference in
tumor incidence for these data underscores
the importance of not attaching too much
weight to anyone experiment. For example,
at weeks 16 and 17 of the first experiment
(8), the tumor incidence was significantly
higher for mice exposed to MF, tentatively
suggesting a role for MF as a tumor co-pro-
moter. However, byweek 23 this difference
had disappeared and, in retrospect, it was
Table 1. Results fortumor incidence, multiplicity, and yield atweek23
Experiment
1 2 3
Numberofmice
Magnetic field 47 47 47
Sham 48 47 48
Numberofmicewith one ornmoretumors(%tumorincidence)
Magneticfield 13(27.7%) 7(14.9%) 8(17.0%)
Sham 9(18.8%) 7(14.9%) 18(37.5%)
Significance level 0.34 1 0.04
Conservative confidence limitsfortumorincidence
Magnetic field (15.6,42.6) (6.2,28.3) (7.7,30.8)
Sham (9.0,32.6) (6.2,28.3) (24.0,52.7)
Total numbers oftumors across all mice in each group
Magneticfield 86 33 27
Sham 48 50 86
Significance level 0.15 0.26 0.01*
Average numberoftumors per mouse
Magnetcfield 2.15 0.7 0.5
Sham 1.19 1.04 1.64
*Denotes statistical significance (p<0.05).
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most likely due to a temporary rise in
tumor incidence among MF-exposed mice,
coupled with a static response in the sham.
In the third experiment in this series, tumor
incidence and yield at all times through
week 23 were significantly higher in mice
exposed to sham conditions. These differ-
ences were statistically significant for tumor
incidence (p = 0.04), as well as for the dis-
tribution of tumors between groups (p =
0.01), and suggest MF may have exerted a
protective effect. No explanation can be
offered for this observation except that the
experimental design accepts the probability
of making a type 1 error 5% of the time.
The results of a recent supplementary
experiment (data not shown) suggests the
observed differences in the third experiment
could also be due to chance. In this supple-
mentary 30-week experiment, two identi-
cally treated DMBA-initiated, PMA-pro-
moted groups (i.e., no sham or MF expo-
sures) were monitored weekly for changes
in tumor incidence, multiplicity, and yield.
These parameters varied by a factor of 2
between the groups during the first 10
weeks of tumor promotion and, while the
tumor incidences converged at 23 weeks,
the difference in tumor yields remained sig-
nificant (unpublished data). Speculating
further, if this supplementary experiment
had been one of the three replicates dis-
cussed here, MF would likely have been
classified either as a co-promoter or an
antipromoter depending on which group
had been selected as the sham.
In a retrospective assessment ofvariation
among the three replicate experiments,
tumor incidence and yield in the shams var-
ied by factors of2 and 2.5, respectively. In a
previous discussion of experimental design,
as published in the preliminary study (7),
the random variation in tumor yield and
incidence had been considered to be no
more than 1.4 and 1.5, respectively. Clearly,
these latter predictions underestimate the
variability in the response ofSENCAR mice
to the initiation/promotion protocol. When
this added variability is considered, the
smallest relative risk that can be declared sig-
nificant (when the background tumor inci-
dence in the sham is 0.2-0.3) was judged to
be 2 for asample size of48 mice. Such adif-
ference would have an 80% chance ofbeing
detected at the 5% level. The variability
inherent in the SENCAR mouse skin model
is also evident from the work of Bull et al.
(13), who found that for multiple experi-
ments with benzo[a]pyrene/PMA as initia-
tor/promoter, the tumor yield varied by a
factor of6. In addition, these authors found
that the SENCAR mouse skin tumor model
gave a false negative rate of 60% for 20
known carcinogens (14). The variability in
the tumor data, apparently due to chance,
and the potentially high false negative rate
make it difficult to accept a marginal
response in tumor incidence or yield as sta-
tistically significant and underscore the
problems associated with trying to assign a
co-promotional effect to MF using the
SENCARmouseskin tumormodel.
When the experiments described here
began in 1989, there was no plausible
mechanism ofaction to guide experimental
design, and the use ofa traditional bioassay
for genotoxocity was accepted as a starting
point for the investigation. Since then, the-
oretical arguments (14) and some empirical
evidence (15-19) suggest that magnetic
fields may be able to indirectly amplify or
modulate some biological output or func-
tion that cannot be detected by simply
enumerating tumors. Based solely on the
analysis of tumor count data, the present
study does not support a role for MF as a
strong co-promoter in the SENCAR mouse
skin tumor model. However, the poor sen-
sitivity associated with this mouse model
means that any weak co-promotional effect
associated with MF would, most likely, go
undetected.
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